BP1073

Perindopril erbumine

British Pharmacopoeia (BP) Reference Standard

• Synonim(y): (2S,3aS,7aS)-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid tert-butylamine salt, Perindopril tert-butylamine, S-9490
• Wzór empiryczny (zapis Hilla): C₁₉H₃₂N₂O₅ · C₄H₁₁N
• Numer CAS: 107133-36-8
• Masa cząsteczkowa: 441.60
• UNSPSC Code: 41116107
• NACRES: NA.24
• MDL number: MFCD02313824

Właściwości

• grade: pharmaceutical primary standard
• API family: perindopril
• form: solid
• shelf life: limited shelf life, expiry date on the label
• manufacturer/tradename: BP
• application(s): pharmaceutical; pharmaceutical small molecule
• format: neat
• storage temp.: 2-8°C
• SMILES string: CC(C)(C)N.CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC
• InChI: 1S/C19H32N2O5.C4H11N/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24;1-4(2,3)5/h12-16,20H,4-11H2,1-3H3,(H,23,24);5H2,1-3H3/t12-,13-,14-,15-,16-;/m0./s1
• InChI key: IYNMDWMQHSMDDE-MHXJNQAMSA-N
• Gene Information: human ... ACE(1636)

Opis

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Perindopril erbumine BP Reference standard, intended for use in laboratory tests only as specifically prescribed in the British Pharmacopoeia.

Also used in monographs such as:

Perindopril Erbumine Tablets

Biochem/physiol Actions

Perindopril erbumine is an angiotensin converting enzyme (ACE) inhibitor; antihypertensive.

Perindopril erbumine is an angiotensin converting enzyme (ACE) inhibitor; antihypertensive; becomes hydrolyzed in vivo to the active diacid metabolite; unlike the other ACE inhibitors, inhibits tumor growth in hepatocellular carcinoma cells due to suppression of VEGF levels; also suppresses angiotensin II production in vitro. Long-term therapy with this agent has a beneficial effect on the cerebral circulation by improving cerebral perfusion reserve in patients with previous minor stroke.

Packaging

Unit quantity: 100 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia

Other Notes

Sales restrictions may apply.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Piktogramy: GHS08
• Słowo ostrzegawcze: Warning
• Kody zagrożeń: H361d
• Ostrzeżenia: P201 - P202 - P280 - P308 + P313 - P405 - P501
• Hazard Classifications: Repr. 2
• Klasa składowania: 11 - Combustible Solids
• Co się dzieje?: WGK 3
• Temperatura zapłonu (°F): Not applicable
• Temperatura zapłonu (°C): Not applicable